KALA BIO, Inc. (FRA:27F0)
Germany · Delayed Price · Currency is EUR 1.128
+0.397 (54.31%)
Last updated: Dec 1, 2025, 3:56 PM CET
KALA BIO Company Description
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases.
The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases.
Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases.
The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023.
KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
KALA BIO, Inc.
| Country | United States |
| Founded | 2009 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 38 |
Contact Details
Address: 1167 Massachusetts Avenue Arlington, Delaware 02476 United States | |
| Phone | 781 996 5252 |
| Website | kalarx.com |
Stock Details
| Ticker Symbol | 27F0 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |